Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of CC-99282 in Relapsed or Refractory Non-Hodgkin Lymphomas
2024-515690-10-00Phase 2Authorised
- Sponsor
- Celgene Corporation
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of golcadomide in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and 2 more (6 arms), sponsored by Celgene Corporation. Planned start Sep 2024; status: authorised.
02
Drugs
golcadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2024-515690-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515690-10-00.